tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Schlegel A et al. Hypothermic Oxygenated Perfusion (HOPE) downregulates the immune response in a rat model of liver transplantation. 2014 Ann. Surg. pmid:25243553
Colombani PM et al. Liver transplantation in infants younger than 1 year of age. 1996 Ann. Surg. pmid:8645039
Stratta RJ et al. Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction. 1999 Ann. Surg. pmid:10235529
Shapiro R et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. 2003 Ann. Surg. pmid:14530723
Fealy MJ et al. Efficacy of rapamycin and FK 506 in prolonging rat hind limb allograft survival. 1994 Ann. Surg. pmid:7507657
Ozawa K et al. An appraisal of pediatric liver transplantation from living relatives. Initial clinical experiences in 20 pediatric liver transplantations from living relatives as donors. 1992 Ann. Surg. pmid:1280074
Vivarelli M et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. 2008 Ann. Surg. pmid:18948815
Abu-Elmagd K et al. Clinical intestinal transplantation: a decade of experience at a single center. 2001 Ann. Surg. pmid:11524593
Lerut J et al. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study. 2008 Ann. Surg. pmid:19092340
McCourtie AS et al. Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition. 2010 Ann. Thorac. Surg. pmid:20494024
Laubach VE Invited commentary. 2010 Ann. Thorac. Surg. pmid:20494025
Li S et al. Intrathymic inoculation of donor bone marrow induces long-term acceptance of lung allografts. 2003 Ann. Thorac. Surg. pmid:12537225
Sugita M et al. Pharmacologic modulation of alveolar liquid clearance in transplanted lungs by phentolamine and FK506. 2009 Ann. Thorac. Surg. pmid:19699927
Moffatt-Bruce S Invited commentary. 2009 Ann. Thorac. Surg. pmid:19699928
Thyagarajan GK et al. FK506-induced fulminant leukoencephalopathy after single-lung transplantation. 1997 Ann. Thorac. Surg. pmid:9386723
Leshnower BG et al. Cyclosporine preserves mitochondrial morphology after myocardial ischemia/reperfusion independent of calcineurin inhibition. 2008 Ann. Thorac. Surg. pmid:18805178
Chambers DJ Invited commentary. 2008 Ann. Thorac. Surg. pmid:18805179
Nathan M et al. Cyclosporin A but not FK-506 protects against dopamine-induced apoptosis in the stunned heart. 2005 Ann. Thorac. Surg. pmid:15854943
Hirai T et al. A short course of FK506 can induce limited donor-specific graft acceptance. 1994 Ann. Thorac. Surg. pmid:7520685
Armitage JM et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. 1992 Ann. Thorac. Surg. pmid:1379032
Oto T et al. Calcineurin inhibitor-related cholestasis complicating lung transplantation. 2010 Ann. Thorac. Surg. pmid:20417810
Groetzner J et al. Cardiac transplantation in pediatric patients: fifteen-year experience of a single center. 2005 Ann. Thorac. Surg. pmid:15620914
Inutsuka K et al. Reconstruction of trachea and carina with immediate or cryopreserved allografts in dogs. 1996 Ann. Thorac. Surg. pmid:8893587
Bolman RM Advantage--FK 506: reduced chronic rejection for lung transplant recipients. 1995 Ann. Thorac. Surg. pmid:7545888
Keenan RJ et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. 1995 Ann. Thorac. Surg. pmid:7545889
Muraki Y et al. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. 2011 Oct-Dec Ann. Transplant. pmid:22210422
Boratyńska M et al. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection. 2006 Ann. Transplant. pmid:17494290
Grochowiecki T et al. A retrospective study of steroid elimination in simultaneous pancreas and preemptive kidney transplant (Sppre-Ktx) recipients. 2006 Ann. Transplant. pmid:17494291
Fox BD et al. Tacrolimus Levels Are Not Associated with Risk of Malignancy in Lung Transplant Recipients. 2017 Ann. Transplant. pmid:29133776
Legris T et al. Humoral immunity after kidney transplantation: impact of two randomized immunosuppressive protocols. 2013 Ann. Transplant. pmid:24231646
Gijsen VM et al. Tacrolimus-induced nephrotoxicity and genetic variability: a review. 2012 Apr-Jun Ann. Transplant. pmid:22743729
Urbanowicz T et al. Induction therapy, tacrolimus plasma concentration, and duration if intensive care unit stay are risk factors for peripheral leucopenia following heart transplantation. 2014 Ann. Transplant. pmid:25274118
Baron PW et al. Post-Transplant Diabetes Mellitus After Kidney Transplant in Hispanics and Caucasians Treated with Tacrolimus-Based Immunosuppression. 2017 Ann. Transplant. pmid:28533501
Furmańczyk A et al. Atypical calcineurin inhibitor-induced haemolytic uremic syndrome after liver transplantation. 2009 Oct-Dec Ann. Transplant. pmid:20009155
Gerlach UA et al. Aspergillus spondylodiscitis after multivisceral transplantation. 2009 Oct-Dec Ann. Transplant. pmid:20009156
Malinowski M et al. Effect of tacrolimus dosing on glucose metabolism in an experimental rat model. 2010 Jul-Sep Ann. Transplant. pmid:20877268
Roan JN et al. Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. 2013 Ann. Transplant. pmid:23792500
El-Agroudy AE et al. Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications. 2008 Ann. Transplant. pmid:19034223
Figurski MJ et al. Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. 2012 Jan-Mar Ann. Transplant. pmid:22466911
Acott P and Babel N BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes? 2012 Jan-Mar Ann. Transplant. pmid:22466913
Zahn A et al. Mycophenolate mofetil combination therapy improves survival after liver transplantation. A single-center retrospective analysis. 2013 Ann. Transplant. pmid:24088725
Park S et al. Reduced Tacrolimus Trough Level Is Reflected by Estimated Glomerular Filtration Rate (eGFR) Changes in Stable Renal Transplantation Recipients: Results of the OPTIMUM Phase 3 Randomized Controlled Study. 2018 Ann. Transplant. pmid:29891834
Rostaing L et al. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. 2014 Ann. Transplant. pmid:25017487
Jannot M et al. Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge. 2014 Ann. Transplant. pmid:24999809
Urbanowicz T et al. Comparison of conventional tacrolimus versus prolong release formula as initial therapy in heart transplantation. 2014 Ann. Transplant. pmid:24949728
Hošková L et al. Comparison of Cystatin C and NGAL in Early Diagnosis of Acute Kidney Injury After Heart Transplantation. 2016 Ann. Transplant. pmid:27226081
Kitazawa F et al. Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. 2017 Ann. Transplant. pmid:28947731
Hirano Y et al. Prolonged Administration of Twice-Daily Bolus Intravenous Tacrolimus in the Early Phase After Lung Transplantation. 2017 Ann. Transplant. pmid:28798289
Illsinger S et al. Effect of tacrolimus on energy metabolism in human umbilical endothelial cells. 2011 Apr-Jun Ann. Transplant. pmid:21716189
Mijal J et al. Formation of synapses between dendritic cells and lymphocytes in skin lymph in an allogeneic reaction. 2002 Ann. Transplant. pmid:12854345